Product Description
GlaxoSmithKline was developing gsk-548470, an oral HIV-1 RT Inhibitor for Chronic Hepatitis B Untreated With Nucleic Acid Analogue. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01480284)
Mechanisms of Action: HIV-1 RT Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Other|Hepatitis B, Chronic|Hepatitis A
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| NCT01475851 | P3 |
Completed |
Hepatitis A|Hepatitis B, Chronic |
2013-06-01 |
2019-03-19 |
Treatments |
|
| NCT01480284 | P3 |
Completed |
Hepatitis B, Chronic|Hepatitis A |
2013-01-01 |
2019-03-19 |
Treatments |
|
| JapicCTI-111705 | P3 |
Completed |
Other |
None |
|||
| JapicCTI-111704 | P3 |
Completed |
Unknown |
None |
Recent News Events
Date |
Type |
Title |
|---|